Division of PET Imaging, Shiga Medical Center Research Institute, 5-4-30, Moriyama, Moriyama, Shiga, 524-8524, Japan.
Department of Radiology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 465, Kajiicho, Kamigyo-ku, Kyoto, 602-8566, Japan.
Ann Nucl Med. 2019 May;33(5):368-373. doi: 10.1007/s12149-019-01337-w. Epub 2019 Jan 28.
Increased F-fluorodeoxyglucose (FDG) uptake in the tonsils after the completion of chemotherapy in patients with lymphoma may be misdiagnosed as tumor recurrence. This study aimed to investigate the changes in physiological FDG uptake in the tonsils during and after chemotherapy in pediatric patients with lymphoma.
A total of 47 FDG-PET/CT scans acquired from 13 pediatric patients with lymphoma (before chemotherapy [preC] = 9; during chemotherapy [durC] = 12; within 1 month after the end of chemotherapy [endC] = 11; and after achieving complete response [postC] = 15) were retrospectively included in this study. FDG uptake in the palatine tonsils was assessed using maximum standardized uptake value (SUV). The relative size of the palatine tonsils was calculated as the tonsil-pharyngeal ratio (TPR). Serial changes in the SUV and TPR were evaluated.
The mean SUV was 3.7 ± 1.7, 2.6 ± 0.7, 2.3 ± 0.8, and 6.2 ± 1.6, at the preC, durC, endC, and postC scans, respectively (p < 0.0001); TPR was 59.0 ± 11.2%, 58.3 ± 9.4%, 54.4 ± 7.9%, and 62.2 ± 12.0% in these groups, respectively, with no significant inter-group differences. TPR and SUV showed no correlation.
Increased physiological FDG uptake in the tonsils is commonly observed after the completion of chemotherapy, even in the absence of reactive hypertrophy.
淋巴瘤患者化疗完成后,扁桃体 F-氟脱氧葡萄糖(FDG)摄取增加可能被误诊为肿瘤复发。本研究旨在探讨儿童淋巴瘤患者化疗期间和化疗后扁桃体生理性 FDG 摄取的变化。
回顾性纳入 13 例淋巴瘤儿童患者的 47 次 FDG-PET/CT 扫描(化疗前[preC] = 9;化疗中[durC] = 12;化疗结束后 1 个月内[endC] = 11;达到完全缓解后[postC] = 15)。使用最大标准化摄取值(SUV)评估腭扁桃体 FDG 摄取。腭扁桃体大小相对比计算为扁桃体-咽腔比(TPR)。评估 SUV 和 TPR 的系列变化。
preC、durC、endC 和 postC 扫描时 SUV 平均值分别为 3.7 ± 1.7、2.6 ± 0.7、2.3 ± 0.8 和 6.2 ± 1.6(p < 0.0001);TPR 分别为 59.0 ± 11.2%、58.3 ± 9.4%、54.4 ± 7.9%和 62.2 ± 12.0%,各组间无显著差异。TPR 和 SUV 之间无相关性。
化疗完成后,即使没有反应性肥大,也常观察到扁桃体生理性 FDG 摄取增加。